MHRAsafety guidance83% confidence
Field Safety Notices: 22 to 26 June 2026
Source: MHRA
Why This Matters
Why this matters: sets a safety guidance precedent in the same sub-indication (lung cancer) as Roche.
Regulatory Analysis
List of Field Safety Notices from 22 to 26 June 2026.
Supporting Context
- Therapeutic area
- Oncology · NSCLC
- Sub-indication
- Lung Cancer
Related signal: Divarasib Study in Untreated Advanced NSCLC Shows Promise for Safety and Efficacy